Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study

Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study

It is very important to explore how we can reduce urinary albumin excretion which is an independent risk factor for ischemic heart disease. In this study, we retrospectively evaluated the effects of RAS inhibitor therapy on diabetic nephropathy in Japanese subjects whose urinary albumin levels were...

Full description

Bibliographic Details
Main Authors: Hidenori Hirukawa, Shinji Kamei, Tomohiko Kimura, Atsushi Obata, Kenji Kohara, Fuminori Tatsumi, Masashi Shimoda, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2018/9435401
id doaj-991aba87ebeb4e1f8ccde23f87a90c59
record_format Article
spelling doaj-991aba87ebeb4e1f8ccde23f87a90c592020-11-24T20:44:37ZengHindawi LimitedJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/94354019435401Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical StudyHidenori Hirukawa0Shinji Kamei1Tomohiko Kimura2Atsushi Obata3Kenji Kohara4Fuminori Tatsumi5Masashi Shimoda6Shuhei Nakanishi7Tomoatsu Mune8Kohei Kaku9Hideaki Kaneto10Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanIt is very important to explore how we can reduce urinary albumin excretion which is an independent risk factor for ischemic heart disease. In this study, we retrospectively evaluated the effects of RAS inhibitor therapy on diabetic nephropathy in Japanese subjects whose urinary albumin levels were within normal range. We enrolled 100 subjects with type 2 diabetes who did not take any renin-angiotensin system (RAS) inhibitor. We defined the subjects taking RAS inhibitor for more than 3 years as RAS inhibitor group. RAS inhibitor exerted protective effect on the progression of urinary albumin excretion in subjects with type 2 diabetes without diabetic nephropathy. In addition, RAS inhibitor exerted more protective effects on renal function especially in subjects with poor glycemic control. In conclusion, RAS inhibitor could protect renal function against the deleterious effect of chronic hyperglycemia in Japanese subjects with type 2 diabetes even before the onset of diabetic nephropathy.http://dx.doi.org/10.1155/2018/9435401
collection DOAJ
language English
format Article
sources DOAJ
author Hidenori Hirukawa
Shinji Kamei
Tomohiko Kimura
Atsushi Obata
Kenji Kohara
Fuminori Tatsumi
Masashi Shimoda
Shuhei Nakanishi
Tomoatsu Mune
Kohei Kaku
Hideaki Kaneto
spellingShingle Hidenori Hirukawa
Shinji Kamei
Tomohiko Kimura
Atsushi Obata
Kenji Kohara
Fuminori Tatsumi
Masashi Shimoda
Shuhei Nakanishi
Tomoatsu Mune
Kohei Kaku
Hideaki Kaneto
Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study
Journal of Diabetes Research
author_facet Hidenori Hirukawa
Shinji Kamei
Tomohiko Kimura
Atsushi Obata
Kenji Kohara
Fuminori Tatsumi
Masashi Shimoda
Shuhei Nakanishi
Tomoatsu Mune
Kohei Kaku
Hideaki Kaneto
author_sort Hidenori Hirukawa
title Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study
title_short Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study
title_full Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study
title_fullStr Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study
title_full_unstemmed Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study
title_sort administration of ras inhibitor before the onset of diabetic nephropathy counteracts the adverse effect of chronic hyperglycemia and reduces the augmentation of urinary albumin excretion: a retrospective clinical study
publisher Hindawi Limited
series Journal of Diabetes Research
issn 2314-6745
2314-6753
publishDate 2018-01-01
description It is very important to explore how we can reduce urinary albumin excretion which is an independent risk factor for ischemic heart disease. In this study, we retrospectively evaluated the effects of RAS inhibitor therapy on diabetic nephropathy in Japanese subjects whose urinary albumin levels were within normal range. We enrolled 100 subjects with type 2 diabetes who did not take any renin-angiotensin system (RAS) inhibitor. We defined the subjects taking RAS inhibitor for more than 3 years as RAS inhibitor group. RAS inhibitor exerted protective effect on the progression of urinary albumin excretion in subjects with type 2 diabetes without diabetic nephropathy. In addition, RAS inhibitor exerted more protective effects on renal function especially in subjects with poor glycemic control. In conclusion, RAS inhibitor could protect renal function against the deleterious effect of chronic hyperglycemia in Japanese subjects with type 2 diabetes even before the onset of diabetic nephropathy.
url http://dx.doi.org/10.1155/2018/9435401
work_keys_str_mv AT hidenorihirukawa administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT shinjikamei administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT tomohikokimura administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT atsushiobata administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT kenjikohara administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT fuminoritatsumi administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT masashishimoda administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT shuheinakanishi administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT tomoatsumune administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT koheikaku administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
AT hideakikaneto administrationofrasinhibitorbeforetheonsetofdiabeticnephropathycounteractstheadverseeffectofchronichyperglycemiaandreducestheaugmentationofurinaryalbuminexcretionaretrospectiveclinicalstudy
_version_ 1716816805479055360

Similar Items